J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Kedudukan dalam Saham
#3880
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Harga Saham
$26.58
Disegerakkan terakhir: 2026-07-23
Modal Pasaran
$4.24B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
38.14%
Negara
IN
Perdagangan J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Kategori
Healthcare
Pendapatan untuk J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Pendapatan pada Mar 2026 TTM: $105.10M
Menurut laporan kewangan terkini J. B. Chemicals & Pharmaceuticals Limited, pendapatan semasa syarikat ialah $105.10M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $90.13M, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $67.56M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi J. B. Chemicals & Pharmaceuticals Limited dari 2005 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $105.10M | 1.29% |
| 2025 | $103.76M | 15.12% |
| 2024 | $90.13M | 33.40% |
| 2023 | $67.56M | 1.58% |
| 2022 | $66.51M | -18.43% |
| 2021 | $81.54M | 76.06% |
| 2020 | $46.31M | 12.06% |
| 2019 | $41.33M | 38.74% |
| 2018 | $29.79M | -15.99% |
| 2017 | $35.46M | 12.49% |
| 2016 | $31.52M | 35.13% |
| 2015 | $23.33M | 59.89% |
| 2014 | $14.59M | -23.47% |
| 2013 | $19.06M | -88.54% |
| 2012 | $166.34M | 348.33% |
| 2011 | $37.10M | 12.53% |
| 2010 | $32.97M | 351.68% |
| 2009 | $7.30M | -33.14% |
| 2008 | $10.92M | -33.49% |
| 2007 | $16.41M | -11.60% |
| 2006 | $18.57M | 22.45% |
| 2005 | $15.16M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,578.98% |
IN
|
